Uncategorized
Aerie Pharmaceuticals Reports Year End 2015 Financial Results and Provides Business Update
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and year ended December 31, 2015, along with a general business update. Aerie Highlights With the Company’s successful Rocket 2 topline safety and efficacy readout
